ADAR1 Capital Management LLC Invests $368,000 in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

ADAR1 Capital Management LLC bought a new stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 110,000 shares of the company’s stock, valued at approximately $368,000. ADAR1 Capital Management LLC owned approximately 0.13% of Atea Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in AVIR. BML Capital Management LLC raised its position in shares of Atea Pharmaceuticals by 14.4% in the 4th quarter. BML Capital Management LLC now owns 7,608,312 shares of the company’s stock worth $25,488,000 after buying an additional 958,312 shares during the period. Peapod Lane Capital LLC purchased a new stake in shares of Atea Pharmaceuticals in the fourth quarter worth about $1,101,000. JPMorgan Chase & Co. lifted its position in Atea Pharmaceuticals by 329.7% during the 4th quarter. JPMorgan Chase & Co. now owns 409,259 shares of the company’s stock worth $1,371,000 after acquiring an additional 314,015 shares in the last quarter. FMR LLC boosted its stake in shares of Atea Pharmaceuticals by 2.8% in the third quarter. FMR LLC now owns 6,618,297 shares of the company’s stock valued at $22,171,000 after purchasing an additional 182,174 shares during the period. Finally, Barclays PLC increased its holdings in Atea Pharmaceuticals by 74.5% during the 3rd quarter. Barclays PLC now owns 177,077 shares of the company’s stock worth $593,000 after purchasing an additional 75,624 shares during the last quarter. 86.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, William Blair restated an “outperform” rating on shares of Atea Pharmaceuticals in a research note on Friday, March 7th.

Atea Pharmaceuticals Stock Performance

Atea Pharmaceuticals stock opened at $2.79 on Monday. The firm’s 50 day moving average price is $3.05 and its two-hundred day moving average price is $3.24. Atea Pharmaceuticals, Inc. has a twelve month low of $2.74 and a twelve month high of $4.15. The firm has a market cap of $238.61 million, a PE ratio of -1.35 and a beta of 0.17.

Atea Pharmaceuticals (NASDAQ:AVIR) last issued its earnings results on Thursday, March 6th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Equities analysts anticipate that Atea Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.